442 related articles for article (PubMed ID: 31019051)
21. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
22. A multi-omics approach to Epstein-Barr virus immortalization of B-cells reveals EBNA1 chromatin pioneering activities targeting nucleotide metabolism.
Lamontagne RJ; Soldan SS; Su C; Wiedmer A; Won KJ; Lu F; Goldman AR; Wickramasinghe J; Tang HY; Speicher DW; Showe L; Kossenkov AV; Lieberman PM
PLoS Pathog; 2021 Jan; 17(1):e1009208. PubMed ID: 33497421
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
Bazot Q; Paschos K; Allday MJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
[TBL] [Abstract][Full Text] [Related]
24. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
25. Galectin-9 Facilitates Epstein-Barr Virus Latent Infection and Lymphomagenesis in Human B Cells.
Xu JX; Zhang R; Huang DJ; Tang Y; Ping LQ; Huang BJ; Huang HQ; Busson P; Li J
Microbiol Spectr; 2023 Feb; 11(1):e0493222. PubMed ID: 36622166
[TBL] [Abstract][Full Text] [Related]
26. Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines.
Skalska L; White RE; Parker GA; Turro E; Sinclair AJ; Paschos K; Allday MJ
PLoS Pathog; 2013 Feb; 9(2):e1003187. PubMed ID: 23436997
[TBL] [Abstract][Full Text] [Related]
27. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.
Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J
Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104
[TBL] [Abstract][Full Text] [Related]
28. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
29. Nuclear receptors and their role in Epstein -- Barr virus induced B cell transformation.
Yenamandra SP; Klein G; Kashuba E
Exp Oncol; 2009 Jun; 31(2):67-73. PubMed ID: 19550394
[TBL] [Abstract][Full Text] [Related]
30. A comprehensive single cell data analysis of lymphoblastoid cells reveals the role of super-enhancers in maintaining EBV latency.
Yan B; Wang C; Chakravorty S; Zhang Z; Kadadi SD; Zhuang Y; Sirit I; Hu Y; Jung M; Sahoo SS; Wang L; Shao K; Anderson NL; Trujillo-Ochoa JL; Briggs SD; Liu X; Olson MR; Afzali B; Zhao B; Kazemian M
J Med Virol; 2023 Jan; 95(1):e28362. PubMed ID: 36453088
[TBL] [Abstract][Full Text] [Related]
31. C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.
Cancian L; Bosshard R; Lucchesi W; Karstegl CE; Farrell PJ
PLoS Pathog; 2011 Jul; 7(7):e1002164. PubMed ID: 21857817
[TBL] [Abstract][Full Text] [Related]
32. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.
Harada S; Yalamanchili R; Kieff E
J Virol; 1998 Dec; 72(12):9948-54. PubMed ID: 9811732
[TBL] [Abstract][Full Text] [Related]
33. Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines.
Elliott J; Goodhew EB; Krug LT; Shakhnovsky N; Yoo L; Speck SH
J Virol; 2004 Dec; 78(24):14062-5. PubMed ID: 15564516
[TBL] [Abstract][Full Text] [Related]
34. Multiple Viral microRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus.
Bouvet M; Voigt S; Tagawa T; Albanese M; Chen YA; Chen Y; Fachko DN; Pich D; Göbel C; Skalsky RL; Hammerschmidt W
mBio; 2021 Mar; 12(2):. PubMed ID: 33785626
[TBL] [Abstract][Full Text] [Related]
35. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
36. Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome.
Dunn LEM; Lu F; Su C; Lieberman PM; Baines JD
J Virol; 2023 Feb; 97(2):e0189422. PubMed ID: 36744959
[TBL] [Abstract][Full Text] [Related]
37. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
Rowe M; Raithatha S; Shannon-Lowe C
J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
[TBL] [Abstract][Full Text] [Related]
38. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
Yoo L; Speck SH
J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
[TBL] [Abstract][Full Text] [Related]
39. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.
Cahir-McFarland ED; Carter K; Rosenwald A; Giltnane JM; Henrickson SE; Staudt LM; Kieff E
J Virol; 2004 Apr; 78(8):4108-19. PubMed ID: 15047827
[TBL] [Abstract][Full Text] [Related]
40. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
